Trovagene with new data from testing onvansertib with Zytiga for certain prostate cancer

Trovagene will present new clinical data from its Phase 2 trial of onvansertib, in combination with Zytiga (abiraterone acetate)/prednisone, in metastatic Castration-Resistant Prostate Cancer (mCRPC), will be presented as an oral poster at the 20th Asia-Pacific Prostate Cancer Conference, which will be held August 23-26 in Melbourne, Australia. The data will be presented in an oral, moderated poster session… Continue reading Trovagene with new data from testing onvansertib with Zytiga for certain prostate cancer

Onvansertib in Trovagene trial safe and well tolerated in difficult-to-treat relapsed or refractory AML patients

Trovagene said that additional data from its ongoing Phase 1b/2 study of onvansertib combined with standard-of-care chemotherapy in Acute Myeloid Leukemia (AML) showed response to treatment in patients in the dose-escalation phase of the trial who received onvansertib at 27mg/m2 and 40mg/m2. The greatest anti-leukemic activity, to-date, has been observed in the onvansertib + decitabine arm,… Continue reading Onvansertib in Trovagene trial safe and well tolerated in difficult-to-treat relapsed or refractory AML patients

Trovagene expects additional evidence of clinical efficacy of onvansertib combined with chemoterapy in Acute Myeloid Leukemia

Preliminary efficacy data from Trovagene’s Phase 1b/2 study testing onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia (AML) is encouraging, in particular that it shows some complete and relatively durable responses, said lead investigator of the trial, Dr. Amer Zeidan.